ESH CML/MPN 2025 | Prolonged follow-up of ASC4MORE: investigating the addition of asciminib to imatinib for CML
In this video, Giuseppe Saglio, MD, University of Turin, Turin, Italy, briefly comments on the prolonged follow-up of the ASC4MORE study (NCT03578367), investigating the addition of asciminib to imatinib in patients with chronic myeloid leukemia (CML). This interview took place at the European School of Haematology (ESH) 4th How to Diagnose and Treat: CML/MPN meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that it’s important at the moment just to see how many of these patients will achieve a stable MR4, MR4.5. So we have now 96. I think the last update is probably, yes, around 96. We expected that after three, four years from the start of the therapy. So we have still to wait one year just to see if there is a clear advantage in terms of achieving a deep and stable molecular response...
I think that it’s important at the moment just to see how many of these patients will achieve a stable MR4, MR4.5. So we have now 96. I think the last update is probably, yes, around 96. We expected that after three, four years from the start of the therapy. So we have still to wait one year just to see if there is a clear advantage in terms of achieving a deep and stable molecular response. This is the main result, so although in this case it is not established by the protocol just to stop the therapy, however, I think that many of these patients will try to do it, so we can have an idea of how it will work.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
